|
|
|
Market Research Report
Multiple Sclerosis Therapeutics
|
Multiple Sclerosis Therapeutics published by Global Industry Analysts, Inc. in April, 2010. This report consists of Pages: 430 and the price starts from US $ 3950.
Abstract
This report analyzes the worldwide markets for Multiple Sclerosis Therapeutics
in US$ Billion. The report provides separate comprehensive analytics for the
US, Japan, Europe and Rest of World. Annual estimates and forecasts are
provided for each region for the period 2006 through 2015. The report profiles
45 companies including Bayer Schering Pharma AG, Biogen Idec Inc., Elan
Pharmaceuticals, Inc., Genzyme Corp, Merck Serono SA, Novartis AG,
Sanofi-Aventis SA, and Teva Pharmaceuticals Industries Limited. Market data
and analytics are derived from primary and secondary research. Company
profiles are mostly extracted from URL research and reported select online
sources.
Table of Contents
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
II. EXECUTIVE SUMMARY
1. MARKET HIGHLIGHTS
- Market Snapshots
- Market Drivers
- Market Restraints
- Major Players
2. MARKET OVERVIEW
- Increasing Prevalence of Multiple Sclerosis
- Table 1: World Multiple Sclerosis Prevalence in Thousands by Select
Countries for Years 2001 through 2010 (includes corresponding Graph/Chart)
- Table 2: Prevalence by Types of Multiple Sclerosis (includes corresponding
Graph/Chart)
- MS Therapeutics in the Market
- Key Multiple Sclerosis Drugs
- Interferon Drugs
- Beta Interferon Drugs in Multiple Sclerosis Treatment
- Non-Interferon Drugs
- Non-Interferon Drugs in Multiple Sclerosis Treatment
- High Unmet Need and Rich Pipeline to Expand MS Market
- Challenges Ahead
3. MARKET TRENDS
- Interferon-based Drugs Dominate Multiple Sclerosis Market
- Sales Dip Inevitable for Current Therapies
- Tough Times Ahead for Betaseron
- Oral Drugs in Pipeline to Alter Market Dynamics in MS Therapies
- Competitive Landscape
- Table 3: Global Multiple Sclerosis Market by Leading Drugs (2008 &
2009): Percentage Share Breakdown for Copaxone, Avonex, Rebif, Betaseron, and
Tysabri (includes corresponding Graph/Chart)
4. MULTIPLE SCLEROSIS - DRUG PIPELINE
- Recent Clinical Trial Activity - An Overview
- Drugs Under Development for Treating Multiple Sclerosis
- FTY 720 (Fingolimod)
- Mylinax
- Laquinimod
- Alemtuzumab
- Teriflunomide
- BG-12 (Oral Fumarate)
- MN-166
- Rituxan/MabThera (Rituximab)
- Vaccines for Multiple Sclerosis
5. PRODUCT OVERVIEW
- Definition
- Causes of Multiple Sclerosis
- Different Forms of Multiple Sclerosis
- Pathology
6. RECENT INDUSTRY ACTIVITY
- Acorda Therapeutics Obtains FDA Approval for Fampridine-SR to treat
Multiple Sclerosis
- Novartis Obtains Priority Review Status for Oral Fingolimod from US FDA
- Copaxone Receives FDA Approval for Patients with First Clinical Episode
Suggestive of MS
- Novartis Obtains FDA Approval for Extavia
- Merck Serono Collaborates with Brigham and Women' s Hospital to Extend
Multiple Sclerosis Research
- Merck Serono Announces Encouraging Phase III Results of Oral Mylinax
- Merck Serono Acquires Rights to Apitope' s Multiple Sclerosis Approach
- Teva and Active Biotech Obtains Fast Track Status from FDA for Oral
Laquinimod
- Genzyme Signs an Agreement with Bayer Healthcare
- EMD Serono to Set Up Research Facility in Massachusetts
- EMD Serono Enters into a Partnership with Fast Forward
- Biogen Idec Secures US-FDA Approval for Production Process of TYSABRI®
- Biogen Idec Secures Fast Track Designation from US-FDA for PEGylated
Interferon Beta-1a
- Bayer Schering Pharma Receives SFDA of China Approval for Betaferon®
- Merck Serono Signs an Agreement with Bionomics
- Orasi Medical Establishes New Office in Tokyo
- Merck Serono and Ambrx to Extend Collaboration for Multiple Sclerosis
- Kineta Acquires Novel Therapeutic Compounds from Airmid
- MediciNova Enters into Agreement with Avigen
- Biogen Idec Takes Over Facet Biotech
- Teva Pharmaceutical Industries to Take over CoGenesys
- Merck Serono Introduces RebiSmartTM Electronic Injection Device
- Bayer to Launch Betaferon Titration Pack
- MediciNova Announces Phase II Clinical Trial Results of MN-166
- The Myelin Repair Foundation Signs Strategic Deal with Dalton Pharma
Services
- Acorda Therapeutics Takes Over Neurorecovery
- Bayer to Introduce 30-Gauge Needle for Betaferon®
- Biogen Idec Commences Late-Stage Trial of Oral Compound Bg-12
- Bayer Acquires Biologics Manufacturing Plant from Novartis
7. FOCUS ON SELECT PLAYERS
- Bayer Schering Pharma AG (Germany)
- Biogen Idec Inc. (US)
- Elan Pharmaceuticals, Inc. (US)
- Genzyme Corp. (US)
- Merck Serono SA (Switzerland)
- Novartis AG (Switzerland)
- Sanofi-Aventis SA (France)
- Teva Pharmaceuticals Industries Limited (Israel)
8. GLOBAL MARKET PERSPECTIVE
- Table 4: World Recent Past, Current & Future Analysis for Multiple
Sclerosis Therapeutics by Geographic Region - US, Japan, Europe and Rest of
World- Markets Independently Analyzed with Annual Sales in US$ Billion for
Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 5: World 10-year Perspective for Multiple Sclerosis Therapeutics by
Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe
and Rest of World Markets for Years 2006, 2009 & 2015 (includes
corresponding Graph/Chart)
- Table 6: World Recent Past, Current & Future Analysis for Multiple
Sclerosis Therapeutics by Leading Drugs - Copaxone, Avonex, Rebif, Betaseron,
Tysabri, and Other Drugs Independently Analyzed with Annual Sales in US$
Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 7: World 10-year Perspective for Multiple Sclerosis Therapeutics by
Leading Drugs - Percentage Breakdown of Dollar Sales for Copaxone, Avonex,
Rebif, Betaseron, Tysabri, and Other Drugs for Years 2006, 2009 & 2015
(includes corresponding Graph/Chart)
III. MARKET
1. THE UNITED STATES
- A. Market Analysis
- Overview
- Table 8: US Multiple Sclerosis Prevalence in Thousands for Years 2001
through 2010 (includes corresponding Graph/Chart)
- Strategic Corporate Developments
- Key Players
- Biogen Idec, Inc.
- Elan Pharmaceuticals, Inc.
- EMD Serono, Inc.
- Genzyme Corp.
- B. Market Analytics
- Table 9: US Recent Past, Current & Future Analysis for Multiple
Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US$
Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
2. JAPAN
- A. Market Analysis
- Overview
- Table 10: Japanese Multiple Sclerosis Prevalence in Thousands for Years
2001 through 2010 (includes corresponding Graph/Chart)
- Strategic Corporate Development
- B. Market Analytics
- Table 11: Japanese Recent Past, Current & Future Analysis for
Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in
US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
3. EUROPE
- A. Market Analysis
- Overview
- Table 12: Multiple Sclerosis Prevalence in Select European Countries for
Years 2001 through 2010 (includes corresponding Graph/Chart)
- Low Penetration to Fuel Growth in European MS DMDs Market
- Oral Medication for MS in Near Future
- Strategic Corporate Development
- Key Players
- Bayer Schering Pharma AG (Germany)
- Merck Serono SA (Switzerland)
- Novartis AG (Switzerland)
- Sanofi-Aventis SA (France)
- B. Market Analytics
- Table 13: European Recent Past, Current & Future Analysis for
Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in
US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
4. REST OF WORLD
- A. Market Analysis
- Overview
- Increasing Incidence of Multiple Sclerosis in Canada
- Strategic Corporate Developments
- Key Player
- Teva Pharmaceuticals Industries Limited (Israel)
- B. Market Analytics
- Table 14: Rest of World Recent Past, Current & Future Analysis for
Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in
US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE
|
 |
